Clinical endpoints and subgroup interpretation. Selected publications, evidence context and AUVYRON editorial interpretation.
Publication links open the journal website in a new tab. The publisher may require security verification or a subscription; PubMed provides an alternative citation and abstract.
01
Human · randomized trials
RECONNECT: outcomes and adverse events
Kingsberg SA et al. · Obstetrics & Gynecology November 2019
Study question & design
Two phase 3, double-blind trials studied bremelanotide in premenopausal women with hypoactive sexual desire disorder.
Reported findings
Desire and related distress scores improved compared with placebo. Satisfying sexual-event counts did not differ significantly. Nausea, flushing and headache were more frequent with bremelanotide.
Limits of interpretation
Results apply to the defined diagnosis, population and formulation. Statistical changes in questionnaire scores should not be equated with universal benefit or with approval of an AUVYRON vial.
Simon JA et al. · Journal of Women’s Health March 2022
Study question & design
An analysis of 1,202 participants examined results across prespecified age, weight, body-mass-index and testosterone subgroups.
Reported findings
Improvements in desire and distress were reported in most analyzed subgroups, with exceptions. Hormonal-contraceptive groups did not show identical statistical findings.
Limits of interpretation
These are analyses of the original RECONNECT data, not independent replication. Subgroup estimates do not extend the findings to unstudied populations or formulations.
These notes describe selected publications, not a systematic review. They provide no dosing or treatment instructions. A published study does not establish the identity, purity, safety, efficacy or regulatory approval of an AUVYRON product. For catalog presentations and the photographed vial, see the compound overview.
